Zevra Therapeutics
ZVRA
48 hedge funds and large institutions have $139M invested in Zevra Therapeutics in 2015 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 13 increasing their positions, 9 reducing their positions, and 4 closing their positions.
640% more capital inflows, than outflows
Capital inflows: $31.6M | Capital outflows: $4.26M
375% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 4
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
45% more funds holding
Funds holding: 33 → 48 (+15)
44% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 9
11.03% more ownership
Funds ownership: 37.28% → 48.31% (+11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWA
Arete Wealth Advisors
Chicago,
Illinois
|
+$16.7M |
| 2 |
DA
DSC Advisors
Chicago,
Illinois
|
+$2.99M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.88M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$2.68M |
| 5 |
Goldman Sachs
New York
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$1.14M |
| 2 |
KCM
Kingdon Capital Management
New York
|
-$1.14M |
| 3 |
Millennium Management
New York
|
-$629K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$404K |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$347K |
ZVRA Hedge Fund Activity: Q4 2015 in Review
48 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q4 2015, worth a combined $139M — up 33% from $104M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ZVRA positions and 4 closed out — a net gain of 15 holders — while 13 added to existing stakes and 9 trimmed.
The largest buyer was Arete Wealth Advisors, opening a new position worth an estimated $16.7M. The largest seller was Broadfin Capital, cutting an estimated $1.14M.
- 48 institutional investors held Zevra Therapeutics (ZVRA) as of Q4 2015, up from 33 in Q3 2015.
- Funds reported $139M of Zevra Therapeutics stock for Q4 2015, up 33% quarter-over-quarter.
- 19 funds opened new Zevra Therapeutics positions in Q4 2015 and 4 closed out, a net change of +15 holders.
- The largest Zevra Therapeutics buyer in Q4 2015 was Arete Wealth Advisors, an estimated $16.7M added.
- The largest Zevra Therapeutics seller in Q4 2015 was Broadfin Capital, an estimated $1.14M sold.
Based on aggregated 13F filings for Q4 2015.